JPWO2019160976A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019160976A5 JPWO2019160976A5 JP2020543802A JP2020543802A JPWO2019160976A5 JP WO2019160976 A5 JPWO2019160976 A5 JP WO2019160976A5 JP 2020543802 A JP2020543802 A JP 2020543802A JP 2020543802 A JP2020543802 A JP 2020543802A JP WO2019160976 A5 JPWO2019160976 A5 JP WO2019160976A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- constant domain
- flt3l
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 24
- 102000036639 antigens Human genes 0.000 claims 24
- 108091007433 antigens Proteins 0.000 claims 24
- 239000012634 fragment Substances 0.000 claims 24
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims 12
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims 12
- 101001052849 Homo sapiens Tyrosine-protein kinase Fer Proteins 0.000 claims 9
- 206010039491 Sarcoma Diseases 0.000 claims 9
- 102100024537 Tyrosine-protein kinase Fer Human genes 0.000 claims 9
- 150000001413 amino acids Chemical group 0.000 claims 9
- 239000003446 ligand Substances 0.000 claims 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 8
- 241000282326 Felis catus Species 0.000 claims 8
- 239000003638 chemical reducing agent Substances 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 108060003951 Immunoglobulin Proteins 0.000 claims 4
- 102000018358 immunoglobulin Human genes 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 claims 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 claims 1
- 241000282324 Felis Species 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023118763A JP7756686B2 (ja) | 2018-02-14 | 2023-07-21 | ネコＭｃＤｏｎｏｕｇｈ肉腫（ＦＭＳ）様チロシンキナーゼ３受容体リガンド（ＦＬＴ３Ｌ）に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用 |
| JP2024195419A JP2025013590A (ja) | 2018-02-14 | 2024-11-07 | ネコＭｃＤｏｎｏｕｇｈ肉腫（ＦＭＳ）様チロシンキナーゼ３受容体リガンド（ＦＬＴ３Ｌ）に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862630571P | 2018-02-14 | 2018-02-14 | |
| US62/630,571 | 2018-02-14 | ||
| PCT/US2019/017877 WO2019160976A1 (en) | 2018-02-14 | 2019-02-13 | Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023118763A Division JP7756686B2 (ja) | 2018-02-14 | 2023-07-21 | ネコＭｃＤｏｎｏｕｇｈ肉腫（ＦＭＳ）様チロシンキナーゼ３受容体リガンド（ＦＬＴ３Ｌ）に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021513357A JP2021513357A (ja) | 2021-05-27 |
| JP2021513357A5 JP2021513357A5 (https=) | 2022-02-22 |
| JPWO2019160976A5 true JPWO2019160976A5 (https=) | 2022-02-22 |
| JP7525397B2 JP7525397B2 (ja) | 2024-07-30 |
Family
ID=67619040
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543802A Active JP7525397B2 (ja) | 2018-02-14 | 2019-02-13 | ネコＭｃＤｏｎｏｕｇｈ肉腫（ＦＭＳ）様チロシンキナーゼ３受容体リガンド（ＦＬＴ３Ｌ）に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用 |
| JP2023118763A Active JP7756686B2 (ja) | 2018-02-14 | 2023-07-21 | ネコＭｃＤｏｎｏｕｇｈ肉腫（ＦＭＳ）様チロシンキナーゼ３受容体リガンド（ＦＬＴ３Ｌ）に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用 |
| JP2024195419A Pending JP2025013590A (ja) | 2018-02-14 | 2024-11-07 | ネコＭｃＤｏｎｏｕｇｈ肉腫（ＦＭＳ）様チロシンキナーゼ３受容体リガンド（ＦＬＴ３Ｌ）に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023118763A Active JP7756686B2 (ja) | 2018-02-14 | 2023-07-21 | ネコＭｃＤｏｎｏｕｇｈ肉腫（ＦＭＳ）様チロシンキナーゼ３受容体リガンド（ＦＬＴ３Ｌ）に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用 |
| JP2024195419A Pending JP2025013590A (ja) | 2018-02-14 | 2024-11-07 | ネコＭｃＤｏｎｏｕｇｈ肉腫（ＦＭＳ）様チロシンキナーゼ３受容体リガンド（ＦＬＴ３Ｌ）に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11512127B2 (https=) |
| EP (1) | EP3752195A4 (https=) |
| JP (3) | JP7525397B2 (https=) |
| KR (2) | KR20250139415A (https=) |
| CN (2) | CN119971026A (https=) |
| AU (2) | AU2019222705B2 (https=) |
| BR (1) | BR112020016400A2 (https=) |
| CA (1) | CA3091184A1 (https=) |
| CL (1) | CL2020002088A1 (https=) |
| IL (1) | IL276598A (https=) |
| MX (2) | MX2020008479A (https=) |
| SG (1) | SG11202007702UA (https=) |
| WO (1) | WO2019160976A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019160976A1 (en) * | 2018-02-14 | 2019-08-22 | Viela Bio, Inc. | Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| GB2183661B (en) | 1985-03-30 | 1989-06-28 | Marc Ballivet | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
| AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
| CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
| WO1990014443A1 (en) | 1989-05-16 | 1990-11-29 | Huse William D | Co-expression of heteromeric receptors |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JP3306063B2 (ja) | 1990-08-24 | 2002-07-24 | イグジス， インコーポレイテッド | ランダムコドンを有するオリゴヌクレオチドを合成する方法 |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| EP0563296B1 (en) | 1990-12-20 | 1999-03-17 | Ixsys, Inc. | Optimization of binding proteins |
| AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| AU6132994A (en) | 1993-02-02 | 1994-08-29 | Scripps Research Institute, The | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| US7537932B1 (en) | 1993-05-19 | 2009-05-26 | Schering Corporation | Antibodies that bind purified mammalian FLT3 ligands |
| US7045128B2 (en) | 1993-05-24 | 2006-05-16 | Immunex Corporation | Antibodies against flt3-ligand |
| US5554512A (en) * | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
| US6630143B1 (en) * | 1993-05-24 | 2003-10-07 | Immunex Corporation | Antibodies against flt3 ligand |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6696248B1 (en) | 1995-08-18 | 2004-02-24 | Morphosys Ag | Protein/(poly)peptide libraries |
| AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
| US6331431B1 (en) | 1995-11-28 | 2001-12-18 | Ixsys, Inc. | Vacuum device and method for isolating periplasmic fraction from cells |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| AU8691398A (en) | 1997-08-04 | 1999-02-22 | Ixsys, Incorporated | Methods for identifying ligand specific binding molecules |
| US6602994B1 (en) | 1999-02-10 | 2003-08-05 | Hercules Incorporated | Derivatized microfibrillar polysaccharide |
| ATE482275T1 (de) | 1999-07-02 | 2010-10-15 | Morphosys Ag | Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden |
| SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| JP2005500508A (ja) * | 2000-06-28 | 2005-01-06 | アメリカ合衆国 | ガスセンサのための気体ガス採取装置及びその方法 |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| BR0206364A (pt) * | 2001-01-09 | 2005-08-16 | Baylor Res Inst | Métodos para tratar doenças auto-imunes em um indivìduo e testes diagnósticos in vitro |
| US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| AU2003256299A1 (en) | 2002-07-01 | 2004-01-19 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
| BR0316101A (pt) | 2002-11-07 | 2005-09-27 | Immunogen Inc | Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos |
| CN103251953A (zh) | 2004-07-19 | 2013-08-21 | 约翰·霍普金斯大学 | 供免疫抑制的flt3抑制剂 |
| US20060142430A1 (en) | 2004-12-29 | 2006-06-29 | Harrington John C | Retention and drainage in the manufacture of paper |
| HRP20160855T1 (hr) * | 2008-02-08 | 2016-09-23 | Medimmune, Llc | Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda |
| BR112012009141B1 (pt) | 2009-10-20 | 2020-10-13 | Basf Se | processo para a produção de papel, papelão e cartolina que possuem alta resistência a seco, e, composição aquosa |
| WO2011113041A2 (en) | 2010-03-12 | 2011-09-15 | The Johns Hopkins University | Neutralization of flt3 ligand as a leukemia therapy |
| US9415118B2 (en) | 2013-03-13 | 2016-08-16 | Novartis Ag | Antibody drug conjugates |
| MX2017002081A (es) | 2014-08-15 | 2017-05-23 | Genexine Inc | Metodo para tratar cancer de cuello uterino. |
| WO2019160976A1 (en) | 2018-02-14 | 2019-08-22 | Viela Bio, Inc. | Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases |
-
2019
- 2019-02-13 WO PCT/US2019/017877 patent/WO2019160976A1/en not_active Ceased
- 2019-02-13 SG SG11202007702UA patent/SG11202007702UA/en unknown
- 2019-02-13 BR BR112020016400-3A patent/BR112020016400A2/pt unknown
- 2019-02-13 KR KR1020257030589A patent/KR20250139415A/ko active Pending
- 2019-02-13 AU AU2019222705A patent/AU2019222705B2/en active Active
- 2019-02-13 CN CN202510100026.1A patent/CN119971026A/zh active Pending
- 2019-02-13 KR KR1020207026493A patent/KR102903323B1/ko active Active
- 2019-02-13 US US16/969,774 patent/US11512127B2/en active Active
- 2019-02-13 EP EP19754925.6A patent/EP3752195A4/en active Pending
- 2019-02-13 MX MX2020008479A patent/MX2020008479A/es unknown
- 2019-02-13 CN CN201980013516.0A patent/CN111989117B/zh active Active
- 2019-02-13 CA CA3091184A patent/CA3091184A1/en active Pending
- 2019-02-13 JP JP2020543802A patent/JP7525397B2/ja active Active
-
2020
- 2020-08-09 IL IL276598A patent/IL276598A/en unknown
- 2020-08-12 CL CL2020002088A patent/CL2020002088A1/es unknown
- 2020-08-13 MX MX2024015370A patent/MX2024015370A/es unknown
-
2022
- 2022-07-21 US US17/814,075 patent/US12209123B2/en active Active
-
2023
- 2023-07-21 JP JP2023118763A patent/JP7756686B2/ja active Active
-
2024
- 2024-11-07 JP JP2024195419A patent/JP2025013590A/ja active Pending
- 2024-12-18 US US18/985,999 patent/US20250122276A1/en active Pending
-
2026
- 2026-01-07 AU AU2026200083A patent/AU2026200083A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025016349A5 (https=) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| CN112135626A (zh) | 抗tigit抗体及其用途 | |
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| JP2020514277A5 (https=) | ||
| JP2012526558A5 (https=) | ||
| JP2016505556A5 (https=) | ||
| JP2019516392A5 (https=) | ||
| HRP20131215T1 (hr) | Antagonistiäśka humana monoklonska protutijela specifiäśna za humane slabe epitope | |
| RU2010149746A (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| RU2020130795A (ru) | Нейтрализующие антитела к env вич-1 и их применение | |
| TW201829467A (zh) | 抗ｃｄ３抗體及含有該抗體的分子 | |
| RU2018135550A (ru) | Связывающие ilt7 молекулы и способы их применения | |
| CN113563473A (zh) | 四价双特异性抗体、其制备方法和用途 | |
| RU2014153440A (ru) | Антитела против cd26 и их применение | |
| RU2019135404A (ru) | Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний | |
| JP2020513759A5 (https=) | ||
| RU2019121106A (ru) | Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1) | |
| CN109721656B (zh) | 靶向rankl的治疗性抗体 | |
| JP7717687B2 (ja) | 腎疾患における抗幹細胞因子抗体及びその使用方法 | |
| RU2019103991A (ru) | Анти-il-22r-антитела | |
| JP2021513357A5 (https=) | ||
| US20250163182A1 (en) | Enpp3 and cd3 binding agents and methods of use thereof | |
| CN119775424A (zh) | 抗bcma抗体及其应用 | |
| WO2013186630A2 (en) | Humanized antibodies to ca215 |